

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

BRISTOL-MYERS SQUIBB CO

2. Address:

655 15TH ST NW #300, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: RICHARD THOMPSON

Telephone: 202-783-8618

E-mail (optional): dick.thompson@bms.com

Senate ID #: 7053-12

House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 2,580,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.Con.Res.95, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2007 through 2010. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006. Lobbied to ensure safety of prescription drugs. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL
Covered Official Position (if applicable): N/A
Name: JOHNSON, MARY SUMPTER
Covered Official Position (if applicable): N/A
Name: PERNIE, CHRIS
Covered Official Position (if applicable): N/A
Name: THOMPSON, RICHARD
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: JOHNSON, MARY SUMPTER

Covered Official Position (if applicable): N/A

Name: RYAN, JOHN

Covered Official Position (if applicable): N/A

Name: THOMPSON, RICHARD

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: JOHNSON, MARY SUMPTER

Covered Official Position (if applicable): N/A

Name: PERNIE, CHRIS

Covered Official Position (if applicable): N/A

Name: RYAN, JOHN

Covered Official Position (if applicable): N/A

Name: WARR, DAVID

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL
Covered Official Position (if applicable): N/A
Name: JOHNSON, MARY SUMPTER
Covered Official Position (if applicable): N/A
Name: PERNIE, CHRIS
Covered Official Position (if applicable): N/A
Name: RYAN, JOHN
Covered Official Position (if applicable): N/A
Name: THOMPSON, RICHARD
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote.
H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: JOHNSON, MARY SUMPTER

Covered Official Position (if applicable): N/A

Name: PERNIE, CHRIS

Covered Official Position (if applicable): N/A

Name: THOMPSON, RICHARD

Covered Official Position (if applicable): N/A

Name: WARR, DAVID

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RYAN, JOHN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: PERNIE, CHRIS

Covered Official Position (if applicable): N/A

Name: WARR, DAVID

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Feb 14, 2006

Printed Name and Title: RICHARD THOMPSON - SENIOR VICE PRESIDENT, POLICY & GOVERNMENT AFFAIRS